Loading organizations...

InfoBionic is a technology company.
InfoBionic.Ai develops an advanced remote cardiac monitoring platform, utilizing artificial intelligence to deliver comprehensive, beat-to-beat electrocardiogram data. Its proprietary MoMe™ system, a cloud-based software-as-a-service solution, is designed for accurate and efficient arrhythmia detection via a wearable device. The platform enables continuous, full-disclosure data streaming to clinicians, enhancing diagnostic capabilities.
Nancy Briefs founded InfoBionic in 2011, establishing the company with the core insight that cardiac event monitoring could be significantly improved through a more accessible and continuous remote model. This approach aimed to overcome traditional method limitations, providing "anywhere, anytime" patient data collection and improved event detection.
Clinicians are the primary users of the InfoBionic.Ai platform, leveraging its capabilities for in-depth patient heart health analysis. The company’s vision centers on transforming the efficiency and economics of ambulatory remote patient monitoring. It strives to optimize clinical processes and enhance diagnostic accuracy and accessibility, ultimately supporting better cardiac condition management.
InfoBionic has raised $75.0M across 3 funding rounds.
InfoBionic has raised $75.0M in total across 3 funding rounds.
InfoBionic has raised $75.0M in total across 3 funding rounds.
InfoBionic's investors include Blue Cross and Blue Shield of Kansas, Eagle Proprietary Investments, Excel Venture Management, Safeguard Scientifics, Zaffre Investments, Al Wiegman, Broadview Ventures, Beta Fund, Boardwalk Investment, Boynton, Cherrystone Angels, HTC.
InfoBionic.Ai is a Massachusetts-based digital health company specializing in AI-enabled remote cardiac monitoring systems, recognized as the gold standard for virtual cardiac telemetry.[1][4][5] Its flagship product, the FDA-approved MoMe ARC® platform, provides hospital-grade, continuous ECG monitoring with AI-driven analysis, serving clinicians, hospitals, and patients by detecting arrhythmias and enabling proactive interventions to reduce hospitalizations and improve outcomes.[1][2][4] The platform features interchangeable pod-based sensors tailored to patient acuity, seamless IT integration, and near real-time data transmission, transforming ambulatory remote patient monitoring with high-fidelity data and clinical insights.[1][2][5]
Founded by a team of seasoned entrepreneurs with expertise in healthcare, IT, medical devices, mobile technology, remote monitoring, and cardiology, InfoBionic addressed the complexities of traditional cardiac arrhythmia detection processes.[5] CEO Stuart Long, with prior executive roles at CapsuleTech (acquired by Qualcomm Life) and Philips Healthcare, led the development of the transformative MoMe® platform, starting with innovations like MoMe® Kardia for beat-to-beat monitoring and instant alerts.[5] The company evolved from InfoBionic to InfoBionic.Ai in early 2024, emphasizing AI advancements in ECG analysis and remote telemetry, marked by partnerships like Anumana for earlier condition detection and the MoMe Gateway with NEXA and T-Mobile for scalable data transmission.[3][4][7]
InfoBionic.Ai rides the wave of AI-driven digital health and remote patient monitoring (RPM), capitalizing on post-pandemic demand for virtual cardiac care amid rising cardiovascular disease burdens.[4][5][7] Its timing aligns with healthcare's shift to proactive, data-intensive models, where AI enhances ECG workflows and enables earlier interventions, reducing hospital readmissions.[1][4] Market forces like regulatory pushes for RPM scalability, IT compliance (HIPAA, FDA), and cost efficiencies favor its no-infrastructure platform, influencing the ecosystem through partnerships with institutions, Anumana, and carriers like T-Mobile to standardize high-quality remote telemetry.[2][3][4]
InfoBionic.Ai is poised to expand its MoMe ARC® ecosystem with deeper AI integrations for predictive analytics and broader condition detection, potentially dominating virtual cardiac telemetry as RPM adoption accelerates.[1][4] Trends like AI validation from Mayo Clinic collaborations and "hospital-at-home" expansions will shape its growth, evolving its influence from monitoring leader to full-spectrum cardiac insight provider.[4] This positions it to further transform patient outcomes, tying back to its founding vision of turning cardiac data into actionable, life-improving clinical reality.[1][5]
InfoBionic has raised $75.0M across 3 funding rounds. Most recently, it raised $50.0M Other Equity in September 2018.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Sep 11, 2018 | $50.0M Other Equity | Blue Cross and Blue Shield of Kansas, Eagle Proprietary Investments, Excel Venture Management, Safeguard Scientifics, Zaffre Investments | |
| Aug 5, 2015 | $8.0M Series B | Safeguard Scientifics | Excel Venture Management, Zaffre Investments |
| Apr 1, 2014 | $17.0M Series B | Al Wiegman | Broadview Ventures, Beta Fund, Boardwalk Investment, Boynton, Broadview Ventures, Cherrystone Angels, HTC, Keiretsu Forum, Launchpad Venture Group, Mass Medical Angels, TiE |